Ampio Pharmaceuticals Inc. (AMPE) and Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Comparing side by side

Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) and Oramed Pharmaceuticals Inc. (NASDAQ:ORMP), both competing one another are Biotechnology companies. We will compare their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ampio Pharmaceuticals Inc. 1 0.00 N/A 0.09 4.57
Oramed Pharmaceuticals Inc. 3 22.07 N/A -0.87 0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 has Ampio Pharmaceuticals Inc. and Oramed Pharmaceuticals Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Ampio Pharmaceuticals Inc. 0.00% 0% 0%
Oramed Pharmaceuticals Inc. 0.00% -56.1% -35.2%

Risk and Volatility

Ampio Pharmaceuticals Inc.’s current beta is 0.85 and it happens to be 15.00% less volatile than Standard & Poor’s 500. Competitively, Oramed Pharmaceuticals Inc.’s 34.00% volatility makes it more volatile than Standard & Poor’s 500, because of the 1.34 beta.

Liquidity

The current Quick Ratio of Ampio Pharmaceuticals Inc. is 3.7 while its Current Ratio is 3.7. Meanwhile, Oramed Pharmaceuticals Inc. has a Current Ratio of 5.1 while its Quick Ratio is 5.1. Oramed Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than Ampio Pharmaceuticals Inc.

Analyst Recommendations

The Recommendations and Ratings for Ampio Pharmaceuticals Inc. and Oramed Pharmaceuticals Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Ampio Pharmaceuticals Inc. 0 0 0 0.00
Oramed Pharmaceuticals Inc. 0 0 1 3.00

On the other hand, Oramed Pharmaceuticals Inc.’s potential upside is 646.27% and its average price target is $25.

Insider and Institutional Ownership

Roughly 33.8% of Ampio Pharmaceuticals Inc. shares are held by institutional investors while 18.2% of Oramed Pharmaceuticals Inc. are owned by institutional investors. Ampio Pharmaceuticals Inc.’s share held by insiders are 10.71%. Insiders Comparatively, held 2% of Oramed Pharmaceuticals Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Ampio Pharmaceuticals Inc. -4.19% -6.83% -33.78% -22.26% -86.96% -1.55%
Oramed Pharmaceuticals Inc. -0.54% 5.78% -0.81% 24.07% -34.17% 22%

For the past year Ampio Pharmaceuticals Inc. had bearish trend while Oramed Pharmaceuticals Inc. had bullish trend.

Summary

Oramed Pharmaceuticals Inc. beats on 5 of the 9 factors Ampio Pharmaceuticals Inc.

Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee; and Optina, which has completed Phase II clinical trials for diabetic macular edema. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. The company operates primarily in Israel. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in Jerusalem, Israel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.